207 related articles for article (PubMed ID: 21139240)
1. Onset of clinical effects and plasma concentration of fluvoxamine in Japanese patients.
Katoh Y; Uchida S; Kawai M; Takei N; Mori N; Kawakami J; Kagawa Y; Yamada S; Namiki N; Hashimoto H
Biol Pharm Bull; 2010; 33(12):1999-2002. PubMed ID: 21139240
[TBL] [Abstract][Full Text] [Related]
2. Fluvoxamine as effective as clomipramine against symptoms of severe depression: results from a multicentre, double-blind study.
Zohar J; Keegstra H; Barrelet L
Hum Psychopharmacol; 2003 Mar; 18(2):113-9. PubMed ID: 12590404
[TBL] [Abstract][Full Text] [Related]
3. Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients.
Gerstenberg G; Aoshima T; Fukasawa T; Yoshida K; Takahashi H; Higuchi H; Murata Y; Shimoyama R; Ohkubo T; Shimizu T; Otani K
Psychopharmacology (Berl); 2003 Jun; 167(4):443-8. PubMed ID: 12682708
[TBL] [Abstract][Full Text] [Related]
4. Fluvoxamine and clomipramine in depressed hospitalised patients: results from a randomised, double-blind study.
Ottevanger EA
Encephale; 1995; 21(4):317-21. PubMed ID: 7588171
[TBL] [Abstract][Full Text] [Related]
5. Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation.
Bondolfi G; Chautems C; Rochat B; Bertschy G; Baumann P
Psychopharmacology (Berl); 1996 Dec; 128(4):421-5. PubMed ID: 8986013
[TBL] [Abstract][Full Text] [Related]
6. T3 augmentation of SSRI resistant depression.
Abraham G; Milev R; Stuart Lawson J
J Affect Disord; 2006 Apr; 91(2-3):211-5. PubMed ID: 16483669
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders.
Sonawalla SB; Spillmann MK; Kolsky AR; Alpert JE; Nierenberg AA; Rosenbaum JF; Fava M
J Clin Psychiatry; 1999 Sep; 60(9):580-3. PubMed ID: 10520975
[TBL] [Abstract][Full Text] [Related]
8. Concentration-response relationship for fluvoxamine using remission as an endpoint: a receiver operating characteristics curve analysis in major depression.
Suzuki Y; Fukui N; Sawamura K; Sugai T; Watanabe J; Ono S; Inoue Y; Ozdemir V; Someya T
J Clin Psychopharmacol; 2008 Jun; 28(3):325-8. PubMed ID: 18480690
[TBL] [Abstract][Full Text] [Related]
9. Plasma levels of catecholamine metabolites predict the response to sulpiride or fluvoxamine in major depression.
Ueda N; Yoshimura R; Shinkai K; Nakamura J
Pharmacopsychiatry; 2002 Sep; 35(5):175-81. PubMed ID: 12237788
[TBL] [Abstract][Full Text] [Related]
10. Fluvoxamine versus fluoxetine in major depressive episode: a double-blind randomised comparison.
Dalery J; Honig A
Hum Psychopharmacol; 2003 Jul; 18(5):379-84. PubMed ID: 12858325
[TBL] [Abstract][Full Text] [Related]
11. Fluvoxamine treatment of mixed anxiety and depression: evidence for serotonergically mediated anxiolysis.
Rausch JL; Hobby HM; Shendarkar N; Johnson ME; Li J
J Clin Psychopharmacol; 2001 Apr; 21(2):139-42. PubMed ID: 11270909
[TBL] [Abstract][Full Text] [Related]
12. Antidepressant response and intolerance to SSRI is not influenced by G-protein beta3 subunit gene C825T polymorphism in Japanese major depressive patients.
Kato M; Wakeno M; Okugawa G; Fukuda T; Takekita Y; Hosoi Y; Azuma J; Kinoshita T; Serretti A
Prog Neuropsychopharmacol Biol Psychiatry; 2008 May; 32(4):1041-4. PubMed ID: 18325652
[TBL] [Abstract][Full Text] [Related]
13. Bcl1 polymorphism of the glucocorticoid receptor gene and treatment response to milnacipran and fluvoxamine in Japanese patients with depression.
Takahashi H; Yoshida K; Higuchi H; Kamata M; Inoue K; Suzuki T; Ishigooka J
Neuropsychobiology; 2014; 70(3):173-80. PubMed ID: 25358426
[TBL] [Abstract][Full Text] [Related]
14. Association between -1438G/A promoter polymorphism in the 5-HT(2A) receptor gene and fluvoxamine response in Japanese patients with major depressive disorder.
Sato K; Yoshida K; Takahashi H; Ito K; Kamata M; Higuchi H; Shimizu T; Itoh K; Inoue K; Tezuka T; Suzuki T; Ohkubo T; Sugawara K; Otani K
Neuropsychobiology; 2002; 46(3):136-40. PubMed ID: 12422060
[TBL] [Abstract][Full Text] [Related]
15. Red blood cell triiodothyronine uptake in unipolar major depression: effect of a chronic antidepressant treatment.
Moreau X; Azorin JM; Lejeune PJ; Jeanningros R
Prog Neuropsychopharmacol Biol Psychiatry; 2000 Jan; 24(1):23-35. PubMed ID: 10659981
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis at the first episode to differentiate antidepressant treatment responses in patients with mood and anxiety disorders.
de Kemp EC; Moleman P; Hoogduin CA; Broekman TG; Goedhart A; Schaap CP; van den Berg PC
Psychopharmacology (Berl); 2002 Feb; 160(1):67-73. PubMed ID: 11862375
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients in menopause transition.
Ushiroyama T; Ikeda A; Ueki M
J Med; 2004; 35(1-6):151-62. PubMed ID: 18084873
[TBL] [Abstract][Full Text] [Related]
18. An open pilot study combining risperidone and a selective serotonin reuptake inhibitor as initial antidepressant therapy.
Hirose S; Ashby CR
J Clin Psychiatry; 2002 Aug; 63(8):733-6. PubMed ID: 12197455
[TBL] [Abstract][Full Text] [Related]
19. The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine.
Yoshida K; Higuchi H; Kamata M; Takahashi H; Inoue K; Suzuki T; Itoh K; Ozaki N
J Psychopharmacol; 2007 Aug; 21(6):650-6. PubMed ID: 17092970
[TBL] [Abstract][Full Text] [Related]
20. Serum concentrations of fluvoxamine and clinical effects. A prospective open clinical trial.
Härtter S; Wetzel H; Hammes E; Torkzadeh M; Hiemke C
Pharmacopsychiatry; 1998 Sep; 31(5):199-200. PubMed ID: 9832352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
